HK1158206A1 - Fluorescent regulators of rassf1a expression and human cancer cell proliferation rassf1a - Google Patents
Fluorescent regulators of rassf1a expression and human cancer cell proliferation rassf1aInfo
- Publication number
- HK1158206A1 HK1158206A1 HK11112766.4A HK11112766A HK1158206A1 HK 1158206 A1 HK1158206 A1 HK 1158206A1 HK 11112766 A HK11112766 A HK 11112766A HK 1158206 A1 HK1158206 A1 HK 1158206A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- rassf1a
- expression
- group
- heterogroup
- aryl group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Electroluminescent Light Sources (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18905908P | 2008-08-15 | 2008-08-15 | |
PCT/US2009/004681 WO2010019271A1 (fr) | 2008-08-15 | 2009-08-14 | Régulateurs fluorescents de l'expression de rassf1a et de la prolifération de cellules cancéreuses humaines |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1158206A1 true HK1158206A1 (en) | 2012-07-13 |
Family
ID=41279343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11112766.4A HK1158206A1 (en) | 2008-08-15 | 2011-11-24 | Fluorescent regulators of rassf1a expression and human cancer cell proliferation rassf1a |
Country Status (10)
Country | Link |
---|---|
US (1) | US10457639B2 (fr) |
EP (2) | EP2323982B1 (fr) |
JP (2) | JP2012500197A (fr) |
CN (1) | CN102186820B (fr) |
AT (1) | ATE547403T1 (fr) |
AU (1) | AU2009282451B2 (fr) |
BR (1) | BRPI0917411A2 (fr) |
CA (1) | CA2734225A1 (fr) |
HK (1) | HK1158206A1 (fr) |
WO (1) | WO2010019271A1 (fr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
US20130047297A1 (en) | 2010-03-08 | 2013-02-21 | Robert D. Sammons | Polynucleotide molecules for gene regulation in plants |
US8637679B2 (en) | 2011-03-11 | 2014-01-28 | Council Of Scientific And Industrial Research | Process for the isolation of organic compounds useful for the treatment of cancer |
MX362812B (es) | 2011-09-13 | 2019-02-13 | Monsanto Technology Llc | Metodos y composiciones para el control de malezas. |
AU2012308686B2 (en) | 2011-09-13 | 2018-05-10 | Monsanto Technology Llc | Methods and compositions for weed control |
UA116092C2 (uk) | 2011-09-13 | 2018-02-12 | Монсанто Текнолоджи Ллс | Спосіб та композиція для боротьби з бур'янами (варіанти) |
US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
MX343072B (es) | 2011-09-13 | 2016-10-21 | Monsanto Technology Llc | Metodos y composiciones para controlar malezas. |
US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
CA2848689A1 (fr) | 2011-09-13 | 2013-03-21 | Monsanto Technology Llc | Procedes et compositions de lutte contre les mauvaises herbes |
IN2014MN02404A (fr) | 2012-05-24 | 2015-08-21 | Seeds Ltd Ab | |
CN105358695B (zh) | 2013-01-01 | 2019-07-12 | A.B.种子有限公司 | 将dsRNA引入植物种子以调节基因表达的方法 |
US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
EP2967082A4 (fr) | 2013-03-13 | 2016-11-02 | Monsanto Technology Llc | Procédés et compositions utilisables en vue de la lutte contre les mauvaises herbes |
CA2905027A1 (fr) | 2013-03-13 | 2014-10-09 | Monsanto Technology Llc | Procedes et compositions utilisables pour lutter contre les mauvaises herbes |
WO2014151317A1 (fr) * | 2013-03-15 | 2014-09-25 | Rush University Medical Center | Méthodes de traitement du cancer |
US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
MX359191B (es) | 2013-07-19 | 2018-09-18 | Monsanto Technology Llc | Composiciones y métodos para controlar leptinotarsa. |
US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
MX2016005778A (es) | 2013-11-04 | 2016-12-20 | Monsanto Technology Llc | Composiciones y metodos para controlar infestaciones de plagas y parasitos de los artropodos. |
UA119253C2 (uk) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Спосіб боротьби із вірусом у кліща varroa та у бджіл |
AU2015206585A1 (en) | 2014-01-15 | 2016-07-21 | Monsanto Technology Llc | Methods and compositions for weed control using EPSPS polynucleotides |
EP3125676A4 (fr) | 2014-04-01 | 2018-02-14 | Monsanto Technology LLC | Compositions et procédés pour lutter contre les insectes nuisibles |
CA2953347A1 (fr) | 2014-06-23 | 2015-12-30 | Monsanto Technology Llc | Compositions et methodes de regulation de l'expression genetique par interference par arn |
WO2015200539A1 (fr) | 2014-06-25 | 2015-12-30 | Monsanto Technology Llc | Procédés et compositions pour administrer des acides nucléiques à des cellules végétales et réguler l'expression génique |
EP3174982A4 (fr) | 2014-07-29 | 2018-06-20 | Monsanto Technology LLC | Compositions et méthodes pour lutter contre les insectes nuisibles |
RU2723049C2 (ru) | 2015-01-22 | 2020-06-08 | Монсанто Текнолоджи Ллс | Композиции и способы борьбы с leptinotarsa |
UY36703A (es) | 2015-06-02 | 2016-12-30 | Monsanto Technology Llc | Composiciones y métodos para la administración de un polinucleótido en una planta |
CN108024517A (zh) | 2015-06-03 | 2018-05-11 | 孟山都技术公司 | 用于将核酸引入到植物中的方法和组合物 |
US10173978B2 (en) | 2015-08-05 | 2019-01-08 | Georgetown University | Small molecule androgen receptor inhibitors and methods of use thereof |
CN110785166A (zh) * | 2017-06-12 | 2020-02-11 | 宫田升平 | 抗癌药及其用途 |
CN107266356B (zh) * | 2017-07-25 | 2020-06-26 | 山西省生物研究院有限公司 | 一种作为自分泌运动因子抑制剂的咔唑类化合物及其制备方法和应用 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2235815A1 (de) * | 1972-07-21 | 1974-01-31 | Bayer Ag | Polyazofarbstoffe |
NL8720442A (nl) | 1986-08-18 | 1989-04-03 | Clinical Technologies Ass | Afgeefsystemen voor farmacologische agentia. |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
NZ241954A (en) | 1991-03-15 | 1994-01-26 | Amgen Inc | Compositions of g-csf for pulmonary administration. |
GB9215361D0 (en) | 1992-07-20 | 1992-09-02 | Wellcome Found | Heterocyclic compounds |
JP3690825B2 (ja) * | 1993-07-26 | 2005-08-31 | エーザイ株式会社 | 三環式ヘテロ環含有スルホンアミドおよびスルホン酸エステル誘導体 |
US5834462A (en) * | 1993-07-26 | 1998-11-10 | Eisai Co., Ltd. | Tricyclic heterocyclic sulfonamide and sulfonic ester derivatives |
CA2186412A1 (fr) | 1995-10-31 | 1997-05-01 | Katherine S. Takaki | Agents melatonergiques a base d'ethylaminocarbazole |
DE1042305T1 (de) | 1997-12-22 | 2001-04-19 | Bayer Ag | HEMMUNG DER p38 KINASE UNTER VERWENDUNG VON SYMMETRISCHEN UND ASYMMETRISCHEN DIPHENYLHARNSTOFFEN |
US6713473B1 (en) | 1999-04-20 | 2004-03-30 | Meiji Seika Kaisha, Ltd. | Tricyclic compounds |
CA2394778A1 (fr) | 1999-12-16 | 2002-06-14 | Shiro Miyoshi | Nouveaux composes tricycliques substitues |
WO2001083452A1 (fr) | 2000-04-28 | 2001-11-08 | Asahi Kasei Kabushiki Kaisha | Nouveaux composes tricycliques |
US6506901B2 (en) | 2000-07-17 | 2003-01-14 | Wyeth | Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists |
US8263657B2 (en) * | 2000-12-18 | 2012-09-11 | Institute Of Medicinal Molecular Design, Inc. | Inhibitors against the production and release of inflammatory cytokines |
AU2002228316A1 (en) | 2001-01-29 | 2002-08-12 | Insight Strategy And Marketing Ltd | Carbazole derivatives and their uses as heparanase inhibitors |
WO2002074306A1 (fr) | 2001-03-19 | 2002-09-26 | Asahi Kasei Kabushiki Kaisha | Remedes pour la steatose hepatique |
GB0319151D0 (en) | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Novel compounds |
US20100063126A1 (en) | 2004-06-29 | 2010-03-11 | Jadolabs Gmbh | Carbazole-Derived Pharmaceutical Compositions |
CA2575046A1 (fr) | 2004-08-18 | 2006-02-23 | Ciba Specialty Chemicals Holding Inc. | Photo-initiateurs a base d'ester d'oxime |
ITMI20051523A1 (it) | 2005-08-03 | 2007-02-04 | Acraf | Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo |
CN101252945A (zh) | 2005-09-01 | 2008-08-27 | 科学与工业研究会 | 一种用于治疗前列腺癌的药物组合物 |
CN1807413B (zh) | 2005-09-28 | 2010-05-05 | 中国医学科学院医药生物技术研究所 | 咔唑磺酰胺衍生物及其制备方法 |
BRPI0617364A2 (pt) * | 2005-10-13 | 2011-07-26 | Orchid Res Lab Ltd | compostos heterocÍclicos como inibidores de pstat3/il-6 |
US20100130579A1 (en) | 2006-10-23 | 2010-05-27 | Georgetown University | Cancer therapy |
IL186935A0 (en) | 2006-10-31 | 2008-02-09 | Veridex Llc | Prostate cancer field effect analysis methods and kits |
CA2710520A1 (fr) | 2007-12-28 | 2009-07-09 | John Wayne Cancer Institute | Utilisation d'etat de methylation de locus mint et de genes lies a une tumeur en tant que marqueur de melanome et de cancer du sein |
WO2009118292A1 (fr) | 2008-03-24 | 2009-10-01 | Novartis Ag | Inhibiteurs de métalloprotéases matricielles à base d'arylsulfonamides |
-
2009
- 2009-08-14 AT AT09789145T patent/ATE547403T1/de active
- 2009-08-14 AU AU2009282451A patent/AU2009282451B2/en not_active Ceased
- 2009-08-14 EP EP09789145A patent/EP2323982B1/fr not_active Not-in-force
- 2009-08-14 US US13/059,183 patent/US10457639B2/en active Active
- 2009-08-14 EP EP20120152000 patent/EP2484666A1/fr not_active Withdrawn
- 2009-08-14 JP JP2011523005A patent/JP2012500197A/ja active Pending
- 2009-08-14 WO PCT/US2009/004681 patent/WO2010019271A1/fr active Application Filing
- 2009-08-14 CA CA2734225A patent/CA2734225A1/fr not_active Abandoned
- 2009-08-14 CN CN2009801406819A patent/CN102186820B/zh not_active Expired - Fee Related
- 2009-08-14 BR BRPI0917411A patent/BRPI0917411A2/pt not_active IP Right Cessation
-
2011
- 2011-11-24 HK HK11112766.4A patent/HK1158206A1/xx not_active IP Right Cessation
-
2014
- 2014-05-21 JP JP2014105150A patent/JP2014148545A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN102186820A (zh) | 2011-09-14 |
WO2010019271A8 (fr) | 2011-03-31 |
CN102186820B (zh) | 2013-08-28 |
CA2734225A1 (fr) | 2010-02-18 |
EP2323982B1 (fr) | 2012-02-29 |
WO2010019271A1 (fr) | 2010-02-18 |
JP2012500197A (ja) | 2012-01-05 |
EP2323982A1 (fr) | 2011-05-25 |
US10457639B2 (en) | 2019-10-29 |
AU2009282451B2 (en) | 2014-02-13 |
AU2009282451A1 (en) | 2010-02-18 |
US20110152339A1 (en) | 2011-06-23 |
EP2484666A1 (fr) | 2012-08-08 |
BRPI0917411A2 (pt) | 2015-12-01 |
JP2014148545A (ja) | 2014-08-21 |
ATE547403T1 (de) | 2012-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1158206A1 (en) | Fluorescent regulators of rassf1a expression and human cancer cell proliferation rassf1a | |
MX2009013341A (es) | Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina. | |
WO2010000364A8 (fr) | Dérivé de pyrrolopyridinylpyrimidin-2-ylamine | |
ZA200701137B (en) | Triazolophthalazines | |
IL191832A (en) | Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors | |
EA201390550A1 (ru) | Способы ингибирования пролиферации клеток в egfr-стимулируемых злокачественных опухолях | |
DE502005002697D1 (de) | Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs | |
CU24269B1 (es) | 3- pirimidin- 4-il- oxazolidin- 2- onas inhibidores de la idh mutante | |
TW200942552A (en) | Combination therapy with c-Met and HER antagonists | |
EA201000558A1 (ru) | Производные имидазола | |
TNSN08278A1 (en) | Triazolopyridazines as tyrosine kinase modulators | |
CL2012000913A1 (es) | Uso de una combinacion farmaceutica de compuestos especificos derivados de 4-morfolintieno[3,2-d]pirimidina con 3,4-difluoro-2-(2-fluoro-4-iodofenilamino)fenil)(3-hidroxi-3-((2s)piperidin-2-il)azetidin-1-il)metanona para tratar localmente un tumor solido avanzado o metastasico. | |
MX2011011488A (es) | Derivados de 3-([1,2,3]triazol-4-il)-pirrolo[2,3-b]piridina. | |
TW200730532A (en) | Camptothecin derivatives as chemoradiosensitizing agents | |
ATE512146T1 (de) | Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen | |
MX2010007927A (es) | Derivados de 4-(pirrolo[2,3-c]piridin-3-il)pirimidin-2-ilamina. | |
ATE527998T1 (de) | Illudin-analoga als krebsmittel | |
WO2013192423A3 (fr) | Méthodes et compositions utiles pour traiter les maladies impliquant des protéines de la famille bcl-2 avec des dérivés de quinoline | |
TN2009000389A1 (en) | Pyrido [2,3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer | |
ATE443717T1 (de) | Metastin derivate und ihre verwendung | |
CY1123161T1 (el) | Παραγωγα δι(φαινυλοπροπανοειδους) γλυκερολης για τη θεραπεια του καρκινου | |
MX2007006090A (es) | 2-metilen-19-nor-(20r)-1a-hidroxi-bishomopregnacalciferol. | |
TW200605885A (en) | Multicyclic lonidamine analogs | |
IL198465A0 (en) | Triazabenzo[e]azulene derivatives for the treatment of tumors | |
CA2378187A1 (fr) | Procedes pour traiter les tumeurs resistantes aux therapies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20170814 |